Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.

Mengzhao WangJames Chih-Hsin YangPaul L MitchellJian FangD Ross CamidgeWeiqi NianChao-Hua ChiuJianying ZhouYanqiu ZhaoWu-Chou SuTsung-Ying YangViola W ZhuMichael MillwardYun FanWen-Tsung HuangYing ChengLiyan JiangDaniel BrungsLyudmila Bazhenova Chee Khoon LeeBo GaoYan XuWei-Hsun HsuLi Zheng Pasi A Janne

Published in: Cancer discovery (2022)

We report the discovery and early clinical development of sunvozertinib, a potential treatment option for the unmet medical need of EGFRexon20ins NSCLC. This article is highlighted in the In This Issue feature, p. 1599.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
healthcare
advanced non small cell lung cancer
small molecule
machine learning
high throughput
replacement therapy
climate change